Bolus dose of dexmedetomidine effect on hemodynamic response to laryngoscopy
Phase 3
Recruiting
- Conditions
- Arterial Blood Pressure.Hypertension (arterial)(benign)(essential)(malignant)(primary)(systemic)
- Registration Number
- IRCT20151219025600N5
- Lead Sponsor
- Oroumia University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
normotensive Patients
Stage I-II hypertensive patients
patients at age 40-70
Exclusion Criteria
Difficult intubation
BMI more than 30
Patient receiving Clonidine
Pregnancy
Laryngoscopy more than 20 seconds
Emergency surgery
Patients with heart blocks
ASA class III and more
Patients with pheochromocytoma
Patients with thyroid disorders
Patients with neuropathy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does dexmedetomidine target to attenuate hemodynamic stress in hypertensive patients during laryngoscopy?
How does bolus dexmedetomidine compare to standard-of-care agents like propofol in managing blood pressure spikes during tracheal intubation?
Are there specific biomarkers associated with enhanced response to dexmedetomidine in essential hypertension patients undergoing laryngoscopy?
What adverse events are commonly reported with high-dose dexmedetomidine in phase III trials for systemic hypertension management?
What combination therapies with alpha-2 adrenergic agonists show promise in mitigating malignant hypertension during airway procedures?